Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease

[1]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin2013 Jan;63(1):11-30.23335087SiegelRNaishadhamDJemalA.Cancer statistics2013CA Cancer J Clin2013Jan631113010.3322/caac.21166Search in Google Scholar

[2]Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol2010 Oct;58(4):588-95.10.1016/j.eururo.2010.07.006NovaraGFicarraVAntonelliAArtibaniWBertiniRCariniMValidation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?Eur Urol2010Oct58458895Open DOISearch in Google Scholar

[3]Fujioka T, Obara W, Committee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell C, the Japanese Urological A. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int J Urol2012 Jun;19(6):496-503.FujiokaTObaraWCommittee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell C the Japanese Urological A. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 updateInt J Urol2012Jun19649650310.1111/j.1442-2042.2012.03031.xSearch in Google Scholar

[4]Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, et al. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann2014 Oct;6(4):286-9.10.4103/0974-7796.14097425371602BazarbashiSAlkhateebSAbusamraARabahDAlotaibiMAlmansourMSaudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinomaUrol Ann2014Oct642869Open DOISearch in Google Scholar

[5]Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodriguez C, Duran I, et al. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol2014 Dec;16(12):1043-50.10.1007/s12094-014-1219-125274276BellmuntJPuenteJGarcia de MuroJLainezNRodriguezCDuranISEOM clinical guidelines for the treatment of renal cell carcinomaClin Transl Oncol2014Dec1612104350Open DOISearch in Google Scholar

[6]Ljungberg B, Gudmundsson E, Christensen S, Lundstam S, Swedish Kidney Cancer Quality Register G. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. Scand J Urol2014 Oct;48(5):445-52.10.3109/21681805.2014.898686LjungbergBGudmundssonEChristensenSLundstamSSwedish Kidney Cancer Quality Register G. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register studyScand J Urol2014Oct48544552Open DOISearch in Google Scholar

[7]Campbell L, Nuttall R, Griffiths D, Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer2009 Aug 01;115(15):3457-67.10.1002/cncr.2438919526593CampbellLNuttallRGriffithsDGumbletonM.Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinomaCancer2009Aug 0111515345767Open DOISearch in Google Scholar

[8]Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw2009 Jun;7(6):618-30.1955558410.6004/jnccn.2009.0043MotzerRJAgarwalNBeardCBolgerGBBostonBCarducciMANCCN clinical practice guidelines in oncology: kidney cancerJ Natl Compr Canc Netw2009Jun7661830Search in Google Scholar

[9]Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2016 Sep;27(suppl 5):v58-v68.EscudierBPortaCSchmidingerMRioux-LeclercqNBexAKhooVRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol2016Sep275v58v6810.1093/annonc/mdw328Search in Google Scholar

[10]Zekri J, Dreosti LM, Ghosn M, Hamada E, Jaloudi M, Khorshid O, et al. Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc2015;8:335-44.26251610ZekriJDreostiLMGhosnMHamadaEJaloudiMKhorshidOMultidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementJ Multidiscip Healthc201583354410.2147/JMDH.S85538Search in Google Scholar

[11]Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw2015 Feb;13(2):151-9.2569160610.6004/jnccn.2015.0022MotzerRJJonaschEAgarwalNBeardCBhayaniSBolgerGBKidney cancer, version 3.2015J Natl Compr Canc Netw2015Feb1321519Search in Google Scholar

[12]Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol2015 Jan;93(1):36-49.ZagouriFPeroukidisSTzannisKKoulouliasVBamiasAHellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG)Crit Rev Oncol Hematol2015Jan931364910.1016/j.critrevonc.2014.08.005Search in Google Scholar

[13]Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist2017 Jun;22(6):667-79.10.1634/theoncologist.2016-043528592625BamiasAEscudierBSternbergCNZagouriFDellisADjavanBCurrent Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical EvaluationOncologist2017Jun22666779Open DOISearch in Google Scholar

[14]Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol2016 Jul;70(1):93-105.2693555910.1016/j.eururo.2016.02.029MochHCubillaALHumphreyPAReuterVEUlbrightTM.The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular TumoursEur Urol2016Jul70193105Search in Google Scholar

[15]Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol2010 Jun;17(6):1471-4.10.1245/s10434-010-0985-420180029EdgeSBComptonCC.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol2010Jun17614714Open DOISearch in Google Scholar

[16]Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol2001 Mar 15;19(6):1649-57.10.1200/JCO.2001.19.6.164911250993ZismanAPantuckAJDoreyFSaidJWShvartsOQuintanaDImproved prognostication of renal cell carcinoma using an integrated staging systemJ Clin Oncol2001Mar 15196164957Open DOISearch in Google Scholar

[17]Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol2015 Jun;16(6):676-85.2597959510.1016/S1470-2045(15)70167-1RiniBGoddardAKnezevicDMaddalaTZhouMAydinHA 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studiesLancet Oncol2015Jun16667685Search in Google Scholar

[18]Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, et al. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur Urol2011 Oct;60(4):673-83.2175253310.1016/j.eururo.2011.06.042MargulisVMasterVACostNGLeibovichBCJoniauSKuczykMInternational consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinomaEur Urol2011Oct60467383Search in Google Scholar

[19]Aitchison M, Bray CA, Van Poppel H, Sylvester R, Graham J, Innes C, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer2014 Jan;50(1):70-7.24074763AitchisonMBrayCAVan PoppelHSylvesterRGrahamJInnesCAdjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trialEur J Cancer2014Jan50170710.1016/j.ejca.2013.08.019Search in Google Scholar

[20]Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016 May 14;387(10032):2008-16.2696909010.1016/S0140-6736(16)00559-6HaasNBManolaJUzzoRGFlahertyKTWoodCGKaneCAdjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialLancet2016May 1438710032200816Search in Google Scholar

[21]Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med2016 Dec 08;375(23):2246-54.10.1056/NEJMoa161140627718781RavaudAMotzerRJPandhaHSGeorgeDJPantuckAJPatelAAdjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyN Engl J Med2016Dec 0837523224654Open DOISearch in Google Scholar

[22]Robert J. Motzer NBH, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). ASCO, J Clin Oncol 35, 2017 (suppl; abstr 4507)2017.RobertJ.MotzerNBHFredeDonskovMarineGross-GoupilSergeiVarlamovEvgenyKopyltsovJae-LyunLeeBohuslavMelicharBrianI. RiniToniK. ChoueiriMiladaZemanovaLoriA WoodDirkFahlenkampMartinNeil ReaumeArnulfStenzlWeichaoBaoPaolaAimoneChristianDoehnPaulRussoCoraN. SternbergRandomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)ASCO, J Clin Oncol352017abstr 4507201710.1200/JCO.2017.35.15_suppl.4507Search in Google Scholar

[23]Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. Eur Urol2017 May;71(5):719-22.2798636910.1016/j.eururo.2016.11.034BexAAlbigesLLjungbergBBensalahKDabestaniSGilesRHUpdated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell CarcinomaEur Urol2017May71571922Search in Google Scholar

[24]Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004 Mar;171(3):1071-6.10.1097/01.ju.0000110610.61545.ae14767273FlaniganRCMickischGSylvesterRTangenCVan PoppelHCrawfordED.Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysisJ Urol2004Mar171310716Open DOISearch in Google Scholar

[25]Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007 Dec 22;370(9605):2103-11.10.1016/S0140-6736(07)61904-718156031EscudierBPluzanskaAKoralewskiPRavaudABracardaSSzczylikCBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet2007Dec 223709605210311Open DOISearch in Google Scholar

[26]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007 Jan 11;356(2):115-24.1721552910.1056/NEJMoa065044MotzerRJHutsonTETomczakPMichaelsonMDBukowskiRMRixeOSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007Jan 11356211524Search in Google Scholar

[27]Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010 Feb 20;28(6):1061-8.10.1200/JCO.2009.23.976420100962SternbergCNDavisIDMardiakJSzczylikCLeeEWagstaffJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol2010Feb 2028610618Open DOISearch in Google Scholar

[28]Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol2017 Feb 20;35(6):591-7.2819981810.1200/JCO.2016.70.7398ChoueiriTKHalabiSSanfordBLHahnOMichaelsonMDWalshMKCabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialJ Clin Oncol2017Feb 203565917Search in Google Scholar

[29]Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007 May 31;356(22):2271-81.1753808610.1056/NEJMoa066838HudesGCarducciMTomczakPDutcherJFiglinRKapoorATemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007May 3135622227181Search in Google Scholar

[30]Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer2013 Jun;11(2):161-7.10.1016/j.clgc.2012.10.003HessGBorkerRFonsecaE.Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world settingClin Genitourin Cancer2013Jun1121617Open DOISearch in Google Scholar

[31]Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer2014 Apr 15;110(8):1917-22.2469142510.1038/bjc.2014.25KoJJChoueiriTKRiniBILeeJLKroegerNSrinivasSFirst-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCBr J Cancer2014Apr 151108191722Search in Google Scholar

[32]Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. How to select targeted therapy in renal cell cancer. Ann Oncol2010 Oct;21 Suppl 7:vii59-62.EscudierBAlbigesLBlesiusALoriotYMassardCFizaziK.How to select targeted therapy in renal cell cancerAnn Oncol2010Oct;217vii596210.1093/annonc/mdq371Search in Google Scholar

[33]Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1814-23.2640615010.1056/NEJMoa1510016ChoueiriTKEscudierBPowlesTMainwaringPNRiniBIDonskovFCabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaN Engl J Med2015Nov 0537319181423Search in Google Scholar

[34]Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016 Jul;17(7):917-27.10.1016/S1470-2045(16)30107-327279544ChoueiriTKEscudierBPowlesTTannirNMMainwaringPNRiniBICabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLancet Oncol2016Jul17791727Open DOISearch in Google Scholar

[35]Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med2015 Nov 05;373(19):1803-13.2640614810.1056/NEJMoa1510665MotzerRJEscudierBMcDermottDFGeorgeSHammersHJSrinivasSNivolumab versus Everolimus in Advanced Renal-Cell CarcinomaN Engl J Med2015Nov 0537319180313Search in Google Scholar

[36]Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, et al. Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. Eur Urol2016 Jan;69(1):4-6.2650831210.1016/j.eururo.2015.10.017PowlesTStaehlerMLjungbergBBensalahKCanfieldSEDabestaniSUpdated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted TherapyEur Urol2016Jan69146Search in Google Scholar

[37]Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol2014 Mar;15(3):286-96.10.1016/S1470-2045(14)70030-024556040MotzerRJPortaCVogelzangNJSternbergCNSzczylikCZolnierekJDovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialLancet Oncol2014Mar15328696Open DOISearch in Google Scholar

[38]Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol2014 Sep 01;32(25):2765-72.2504933010.1200/JCO.2013.54.6911MotzerRJBarriosCHKimTMFalconSCosgriffTHarkerWGPhase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaJ Clin Oncol2014Sep 013225276572Search in Google Scholar

[39]Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol2016 Mar;17(3):378-88.10.1016/S1470-2045(15)00515-XArmstrongAJHalabiSEisenTBroderickSStadlerWMJonesRJEverolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialLancet Oncol2016Mar17337888Open DOISearch in Google Scholar

[40]Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol2016 May;69(5):866-74.10.1016/j.eururo.2015.10.04926626617TannirNMJonaschEAlbigesLAltinmakasENgCSMatinSFEverolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 TrialEur Urol2016May69586674Open DOISearch in Google Scholar